ILUSTRASI. A targeted oral drug combination by Novartis won US approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor. REUTERS/Arnd Wiegmann/File Photo
Sumber: Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - FRANKFURT. A targeted oral drug combination by Novartis won US approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumour agnostic.
The Food and Drug Administration early on Thursday granted accelerated approval for the combination of the two drugs Tafinlar and Mekinist for adults and children as young as six with inoperable or metastatic solid tumours with a mutation known as BRAF V600, who have exhausted other treatment options.
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan atau membeli artikel ini.
Sudah berlangganan? Masuk
Berlangganan Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi, bisnis, dan investasi pilihan
Business Insight, Epaper Harian + Tabloid, Arsip Epaper 30 Hari
Gratis uji coba 7 hari pertama. Anda dapat menggunakan akun Google sebagai metode pembayaran.